Amala Maxwell, Suman Pahal, Pinal Chaudhari, Bhim Bahadur Chaudhari, Sameera Peri, Sudheer Moorkoth, Vivek Ghate, Praveen Kumar Vemula, Shaila Lewis
{"title":"Microneedle-Mediated Delivery of Amikacin-Liposomes: A Minimally Invasive Strategy against Bacterial Septicemia","authors":"Amala Maxwell, Suman Pahal, Pinal Chaudhari, Bhim Bahadur Chaudhari, Sameera Peri, Sudheer Moorkoth, Vivek Ghate, Praveen Kumar Vemula, Shaila Lewis","doi":"10.1007/s12247-025-10056-x","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Sepsis is a severe systemic infection with a high mortality rate worldwide. Majorly, sepsis is treated by administering antibiotics including amikacin. Nevertheless, the present course of therapy necessitates frequent bolus doses of amikacin, leading to patient non-adherence, prolonged hospital stays, and regular therapeutic monitoring. Administration of amikacin by the intravenous or intramuscular routes requires precise dosage calculations, and appropriate disposal of sharp wastes. Amikacin’s shorter half-life makes it more challenging to administer intravenously and achieve adequate systemic concentrations. An innovative formulation and delivery approach to combat infection, particularly in a low-resource healthcare setting can be lifesaving to many, by reducing errors due to inappropriate needle disposal and expanding access to outpatient antibiotic treatment.</p><h3>Methods</h3><p>In response to the challenge, novel delivery systems were fabricated, including microneedle (MN) patches containing amikacin (Ak-MN) and amikacin-loaded liposomes (Ak-lip-MN). These systems were designed to offer sustained and extended delivery, to improve the treatment of infections. The Ak-MN and Ak-lip-MN were prepared using the PDMS micro-molding technique and evaluated for their piercing strength, in vivo skin insertion, pharmacokinetics, and stability.</p><h3>Results</h3><p>The higher TEWL value of 375.6 g/m<sup>2</sup>/h and the histological studies showed good MN skin insertion. The developed MN patches demonstrated a prolonged release profile lasting as long as 96 h, with maximum plasma concentrations (C<sub>max</sub>) of 450 ng/mL for Ak-MN and 250 ng/mL for Ak-lip-MN. This can lower continual dosage administration and enhance the antibacterial efficacy at reduced doses, making way for effective treatment approaches for the management of sepsis.</p><h3>Conclusion</h3><p>The study overcomes the drawbacks of traditional intravenous injections, by developing dissolving microneedles with improved therapeutic efficacy.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 4","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-10056-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
Sepsis is a severe systemic infection with a high mortality rate worldwide. Majorly, sepsis is treated by administering antibiotics including amikacin. Nevertheless, the present course of therapy necessitates frequent bolus doses of amikacin, leading to patient non-adherence, prolonged hospital stays, and regular therapeutic monitoring. Administration of amikacin by the intravenous or intramuscular routes requires precise dosage calculations, and appropriate disposal of sharp wastes. Amikacin’s shorter half-life makes it more challenging to administer intravenously and achieve adequate systemic concentrations. An innovative formulation and delivery approach to combat infection, particularly in a low-resource healthcare setting can be lifesaving to many, by reducing errors due to inappropriate needle disposal and expanding access to outpatient antibiotic treatment.
Methods
In response to the challenge, novel delivery systems were fabricated, including microneedle (MN) patches containing amikacin (Ak-MN) and amikacin-loaded liposomes (Ak-lip-MN). These systems were designed to offer sustained and extended delivery, to improve the treatment of infections. The Ak-MN and Ak-lip-MN were prepared using the PDMS micro-molding technique and evaluated for their piercing strength, in vivo skin insertion, pharmacokinetics, and stability.
Results
The higher TEWL value of 375.6 g/m2/h and the histological studies showed good MN skin insertion. The developed MN patches demonstrated a prolonged release profile lasting as long as 96 h, with maximum plasma concentrations (Cmax) of 450 ng/mL for Ak-MN and 250 ng/mL for Ak-lip-MN. This can lower continual dosage administration and enhance the antibacterial efficacy at reduced doses, making way for effective treatment approaches for the management of sepsis.
Conclusion
The study overcomes the drawbacks of traditional intravenous injections, by developing dissolving microneedles with improved therapeutic efficacy.
期刊介绍：
The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories:
Materials science,
Product design,
Process design, optimization, automation and control,
Facilities; Information management,
Regulatory policy and strategy,
Supply chain developments ,
Education and professional development,
Journal of Pharmaceutical Innovation publishes four issues a year.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
